Perspectives of decreasing individual cardiovascular risk in high- and very high risk patients with arterial hypertension, treated with rilmenidine

Perspectives of decreasing individual cardiovascular risk in high- and very high risk patients with arterial hypertension, treated with rilmenidine

Aim. To assess perspectives of decreasing individual cardiovascular event (CVE) risk and surrogate end-point incidence (blood pressure, BP; left ventricular hypertrophy, LVH; pulse wave velocity, PWV), in high- and very high-risk patients with Stage II-III arterial hypertension (AH), during 6-month...

Full description

Bibliographic Details
Main Authors: S. V. Nedogoda, I. V. Marchenko, T. A. Chalyabi, U. A. Brel, V. A. Tsoma, E. A. Prokhorova, E. S. Kesareva
Format: Article
Language:Russian
Published: «SILICEA-POLIGRAF» LLC 2005-06-01
Series:Кардиоваскулярная терапия и профилактика
Subjects:
arterial hypertension
rilmenidine
pulse wave velocity
Online Access:https://cardiovascular.elpub.ru/jour/article/view/967

Similar Items

Similar Items